Do you want to read an article? Please log in or register.
Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab
Diabetic Complications
Related content
RECOMMENDED
Type 2 Diabetes
Effect of a Behavioral Intervention Strategy on Sustained Change in Physical Activity and Sedentary Behavior in Patients With Type 2 Diabetes: The IDES_2 Randomized Clinical Trial
JAMA.
Balducci S, D'Errico V, Haxhi J, Sacchetti M, Orlando G, Cardelli P, Vitale M, Bollanti L, Conti F, Zanuso S, Lucisano G, Nicolucci A, Pugliese G, Italian Diabetes and Exercise Study 2 (IDES_2) Investigators
doi: 10.1001/jama.2019.0922.
COMMENTED
Diabetes - GeneralType 2 DiabetesGlycemic Control
A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study
Diabetes Obes Metab.
Scott R, Morgan J, Zimmer Z, Lam RLH, O'Neill EA, Kaufman KD, Engel SS, Raji A
doi: 10.1111/dom.13473.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial
JAMA.
Davies M, Pieber TR, Hartoft-Nielsen ML, Hansen OKH, Jabbour S, Rosenstock J
doi: 10.1001/jama.2017.14752.
Type 2 Diabetes
Effect of exenatide twice daily and dapagliflozin alone and in combination on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial
Diabetes Obes Metab
van Ruiten CC, van der Aart-van der Beek AB, IJzerman RG, Nieuwdorp M, Hoogenberg K, van Raalte DH, Heerspink HJL
doi: 10.1111/dom.14410
Diabetes - GeneralType 2 DiabetesGlycemic Control
Effects of Insulin Treatment with Glargine or Premixed Insulin Lispro Programs in Type 2 Diabetes Mellitus Patients: A Meta-analysis of Randomized Clinical Trials
Diabetes Technol Ther.
Sun D, Zhang X, Hou XX
doi: 10.1089/dia.2018.0132.
Diabetes - GeneralType 2 Diabetes
Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial
JAMA Cardiol.
Scirica BM, Bhatt DL, Braunwald E, Raz I, Cavender MA, Im K, Mosenzon O, Udell JA, Hirshberg B, Pollack PS, Steg PG, Jarolim P, Morrow DA
doi: 10.1001/
COMMENTED
Type 2 Diabetes
2-year remission of type 2 diabetes and pancreas morphology: a post-hoc analysis of the DiRECT open-label, cluster-randomised trial
★ 2
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Lancet Diabetes Endocrinol
Al-Mrabeh A, Hollingsworth KG, Shaw JAM, McConnachie A, Sattar N, Lean MEJ, Taylor R
doi: 10.1016/S2213-8587(20)30303-X
Diabetes - GeneralType 2 Diabetes
Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial
Diabetes Obes Metab.
Harris SB, Kocsis G, Prager R, Ridge T, Chandarana K, Halladin N, Jabbour S
doi: 10.1111/dom.12892.
Type 2 Diabetes
Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86)
Lancet Diabetes Endocrinol.
Maddaloni E, Coleman RL, Agbaje O, Buzzetti R, Holman RR
doi: 10.1016/S2213-8587(20)30003-6.